Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Studies that have reported lower risk for cardiovascular outcomes in users of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) are limited by residual cofounding and lack of information on prior cardiovascular disease (CVD). This study compared risk of cardiovascular events in patients within routine care settings in Europe and Asia with type 2 diabetes (T2D) initiating empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP-4i) stratified by pre-existing CVD and history of heart failure (HF).
Methods And Results: Adults initiating empagliflozin and DPP-4i in 2014-2018/19 from 11 countries in Europe and Asia were compared using propensity score matching and Cox proportional hazards regression to assess differences in rates of primary outcomes: hospitalisation for heart failure (HHF), myocardial infarction (MI), stroke; and secondary outcomes: cardiovascular mortality (CVM), coronary revascularisation procedure, composite outcome including HHF or CVM, and 3-point major adverse cardiovascular events (MACE: MI, stroke and CVM). Country-specific results were meta-analysed and pooled hazard ratios (HR) with 95% confidence intervals (CI) from random-effects models are presented. In total, 85,244 empagliflozin/DPP4i PS-matched patient pairs were included with overall mean follow-up of 0.7 years. Among those with pre-existing CVD, lower risk was observed for HHF (HR 0.74; 95% CI 0.64-0.86), CVM (HR 0.55; 95% CI 0.38-0.80), HHF or CVM (HR 0.57; 95% CI 0.48-0.67) and stroke (HR 0.79; 95% CI 0.67-0.94) in patients initiating empagliflozin vs DPP-4i. Similar patterns were observed among patients without pre-existing CVD and those with and without pre-existing HF.
Conclusion: These results from diverse patient populations in routine care settings across Europe and Asia demonstrate that initiation of empagliflozin compared to DPP-4i results in favourable cardioprotective effects regardless of pre-existing CVD or HF status.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472675 | PMC |
| http://dx.doi.org/10.1186/s12933-023-01963-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.
Adv Ther
September 2025
Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.
View Article and Find Full Text PDFEffectiveness and Safety of Insulin Glargine 300 U/ml in High-Risk Subgroups (Renal Impairment and Older Age ≥ 70 years) of Insulin-Naïve People with Type 2 Diabetes: A Post hoc Analysis of Real-World ATOS Study.
Diabetes Ther
September 2025
Department of Diabetes and Endocrinology, Guy's and St Thomas' NHS Trust, London, UK.
Introduction: This post hoc analysis of an A Toujeo Observational Study (ATOS) aims to evaluate the real-world effectiveness and safety of insulin glargine 300 U/ml (Gla-300) in high-risk subgroups of insulin-naïve people with type 2 diabetes (PwT2D) from multiple geographical regions (Asia, the Middle East, North Africa, Latin America, and Eastern Europe).
Methods: In these post hoc analyses of ATOS, a real-world, 12-month, prospective study included 4422 insulin-naïve adults (age ≥ 18 years) with type 2 diabetes (T2D) uncontrolled (HbA > 7% and ≤ 11%) on one or more oral antidiabetic drugs (OADs) who initiated Gla-300 treatment as per routine practice. Primary and secondary endpoints were studied according to renal impairment (RI) status (without or with) and age group ( View Article and Find Full Text PDF
[Diffuse lamellar keratitis: sporadic and cluster forms].
Vestn Oftalmol
September 2025
Multidisciplinary Medical Center of Svyatoslav Fedorov Foundation for the Promotion of Advanced Medical Technologies, Moscow, Russia.
Unlabelled: Diffuse lamellar keratitis (DLK) is a known complication of lamellar corneal surgery. The underlying mechanism of the cellular response in DLK is well described. There are two clinical forms - sporadic and cluster - each largely influenced by surgical triggers.
View Article and Find Full Text PDFTesting a Susceptible Population Density Among Other Explanatory Factors of African Swine Fever Spread in Wild Boar Using the Russian Federation Data, 2007-2023.
Transbound Emerg Dis
September 2025
Federal Research Center for Virology and Microbiology - Branch in Nizhny Novgorod, Nizhny Novgorod, Russia.
This study aims to identify the role of various natural, socioeconomic, and demographic factors in the development of the African swine fever (ASF) epizootic among wild boar in the Russian Federation (RF) from 2007 to 2023. In this study, particular emphasis was placed on testing the significance of wild boar population density as a key factor contributing to the spread of ASF within this population. During the study period, 1711 outbreaks in wild boars were reported in the RF, accounting for 41.
View Article and Find Full Text PDFComparative genomic insights into adaptation, selection signatures, and population dynamics in indigenous Indian sheep and foreign breeds.
Front Genet
August 2025
College of Poultry Production and Management, TANUVAS, Hosur, India.
Background: India's indigenous sheep breeds have evolved under extreme and diverse agro-ecological pressures, yet the genomic basis of their resilience and local adaptation remains poorly understood.
Method: This study combines genomic inbreeding estimates, runs of homozygosity (ROH), population structure analyses, and composite selection scans to investigate three native Indian breeds-Changthangi, Deccani, and Garole-within a panel of nine breeds that also includes populations from Africa (Ethiopian Menz), East and South Asia (Tibetan, Chinese Merino, Bangladesh Garole, Bangladesh East), and Europe (Suffolk).
Results: ROH and heterozygosity estimates revealed strong contrasts: Bangladesh East sheep exhibited high genomic inbreeding (F≈14.